Pharmaceutical intermediates
Tucatinib Intermediates
17 pharmaceutical intermediates for Tucatinib. Indication: Breast cancer; colorectal cancer.
About Tucatinib
- Originator
- Array Biopharma
- Indication
- Breast cancer; colorectal cancer
- Approved Date
- 04/17/2020
- NCE Patent
- 04/17/2025
- DS/DP
- 11/16/2025
Available intermediates
17 intermediates currently listed for Tucatinib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| [1,2,4]Triazolo[1,5-a]pyridin-7-ol | 1033810-70-6 | / | / |
| (E)-N'-(2-cyano-4-(3-(1-hydroxy-2-methylpropan-2-yl)thioureido)phenyl)-N,N-dimethylformimidamide | 1429755-57-6 | / | / |
| (2-methyl-4-nitrophenoxy)-[1,2,4]triazolo[1,5-a]pyridine | 937263-44-0 | / | / |
| 4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylaniline | 937263-71-3 | / | / |
| (E)-N'-(2-cyano-4-nitrophenyl)-N,N-dimethylformimidamide | 39263-34-8 | / | / |
| N'-(4-Amino-2-cyanophenyl)-N,N-dimethylformamidine | 194423-17-1 | / | / |
| Chloro-[1,2,4]triazolo[1,5-a]pyridine | 1427452-48-9 | / | / |
| 1-(4-((4-([1,2,4]Triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)amino)quinazolin-6-yl)-3-(1-hydroxy-2-methylpropan-2-y | 1429755-58-7 | / | / |
| 1-(3-cyano-4-((dimethylamino)methyleneamin | 937263-23-5 | / | / |
| (4-chloropyridin-2-yl)-N'-hydroxyformimidamide | 2379814-46-5 | / | / |
| Aminopyridin-4-ol | 33631-05-9 | / | / |
| 4-Chloropyridine-2-carboxamide | 99586-65-9 | / | / |
| Methyl 4-chloropicolinate | 24484-93-3 | / | / |
| 2-Amino-4-chloropyridine | 19798-80-2 | / | / |
| 2-Amino-4-methoxypyridine | 10201-73-7 | / | / |
| 4-METHOXY-PYRIDINE-2-CARBOXYLIC ACID AMIDE | 90151-10-3 | / | / |
| 5-Chloropyridine-2-carboxylic acid | 5470-22-4 | / | / |
Building toward Tucatinib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →